RUA Life Sciences PLC Directorate Change (4361I)

TIDMRUA

RNS Number : 4361I

RUA Life Sciences PLC

11 December 2020

RUA Life Sciences plc

("RUA", the "Company" or the "Group")

Directorate Change

RUA Life Sciences plc (AIM:RUA), the holding company of a group of medical device businesses focused on the exploitation of Elast-Eon(TM), a long-term implantable biostable polymer , announces that Gordon Wright has resigned as a non-executive Director of the Company with effect from 10 December 2020.

As previously reported in the Company's audited results for the year ended 31 March 2020, Gordon, who was the founder of the predecessor AorTech business, has decided to retire from the Board now that the business has been re-established with an exciting future ahead of it. The Directors wish to thank Gordon for his support and guidance over the years and look forward to working with him in his new role as Honorary Life President.

The search for a replacement non-executive Director who will also chair the Company's audit committee is nearing completion and a further announcement will be made in due course.

For further information contact:

RUA Life Sciences plc Tel: [phone]

Bill Brown, Executive Chairman

Shore Capital Tel: [phone]

Tom Griffiths / David Coaten

About RUA Life Sciences

The RUA Life Sciences group was created in April 2020 when RUA Life Sciences Plc (formerly known as AorTech International Plc) acquired RUA Medical Devices Limited to create a fully formed medical device business. RUA Life Sciences is the holding company of the Group's four trading businesses, each exploiting the Group's patented polymer technology.

Our vision is to improve the lives of millions of patients by improving and enabling medical devices with Elast-Eon(TM) , the world's leading long-term implantable polyurethane.

Whether it is licensing Elast-Eon(TM) , manufacturing a device or component or developing next generation medical devices, a RUA Life Sciences business is pursuing our vision.

Elast-Eon (TM)'s biostability is comparable to silicone while exhibiting excellent mechanical, blood contacting and flex-fatigue properties. These polymers can be processed using conventional thermoplastic extrusion and moulding techniques. With over 7 million implants and over 14 years of successful clinical use, RUA's polymers are proven in long-term life enabling applications.

The Group's four business units are:

 
RUA Medical :     End-to-end contract developer and manufacturer 
                   of medical devices and implantable fabric specialist. 
RUA Biomaterials  Licensor of Elast-Eon(TM) polymers to the medical 
 :                 device industry. 
RUA Vascular :    Development of large bore polymer sealed grafts 
                   and soft tissue patches. 
RUA Structural    Development of tri leaflet polymeric heart valves. 
 Heart : 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

BOAZFLFFBLLZFBX

(END) Dow Jones Newswires

December 11, 2020 09:46 ET (14:46 GMT)